Compare Cytokinetics Inc (CYTK) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs DuPont de Nemours Inc — how do they compare? Cytokinetics Inc trades at $76.53 (market cap $10.63B), while DuPont de Nemours Inc trades at $144.5 (market cap $19.51B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays a 1.66% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | DD | |
|---|---|---|
Market Cap | $10.63B | $19.51B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $154.59 |
52-Week Low | $34.31 | $90.24 |
Enterprise Value | $10.74B | $20.90B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
DuPont (DD) trades at $143.64, up 1.47% today, with strong technical momentum as price approaches resistance near $146. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.88 exceeding the $1.76 estimate, and raised full-year 2026 guidance. Recent news highlights contract wins in water treatment and R&D innovation awards, though the stock faces valuation concerns with a P/E of 62 and negative net income in 2025.
The outlook is cautiously optimistic given earnings momentum and analyst bullishness (58% buy ratings), but high valuation and thin profit margins pose risks. The consensus price target of $232.80 suggests significant upside if execution continues, though investors should monitor debt levels and PFAS litigation developments that could impact financials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
